Mizuho Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price

Nkarta (NASDAQ:NKTX) had its price target lowered by equities researchers at Mizuho from $16.00 to $14.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock.

Several other analysts have also weighed in on NKTX. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Nkarta in a report on Thursday, March 27th. Stifel Nicolaus dropped their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 27th. Needham & Company LLC lowered their target price on Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, May 15th. Finally, William Blair restated a “market perform” rating on shares of Nkarta in a research report on Thursday, May 15th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Nkarta has a consensus rating of “Buy” and a consensus price target of $14.33.

Nkarta Trading Up 8.6%

Nkarta stock traded up $0.16 during midday trading on Tuesday, reaching $2.03. 158,902 shares of the stock traded hands, compared to its average volume of 1,125,587. The company has a 50-day simple moving average of $1.82 and a two-hundred day simple moving average of $2.07. The firm has a market cap of $144.04 million, a PE ratio of -1.08 and a beta of 0.72. Nkarta has a 12-month low of $1.31 and a 12-month high of $8.23.

Nkarta (NASDAQ:NKTX) last announced its earnings results on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01. Equities research analysts anticipate that Nkarta will post -1.7 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in NKTX. Invesco Ltd. acquired a new position in shares of Nkarta in the fourth quarter valued at $30,000. Sequoia Financial Advisors LLC bought a new stake in Nkarta in the 4th quarter valued at $31,000. Wealth Enhancement Advisory Services LLC bought a new stake in Nkarta in the 1st quarter valued at $32,000. ProShare Advisors LLC acquired a new position in shares of Nkarta in the 4th quarter valued at $45,000. Finally, Sei Investments Co. bought a new position in shares of Nkarta during the 4th quarter worth about $57,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.